柳药集团
(603368)
| 流通市值：60.30亿 | | | 总市值：60.30亿 |
| 流通股本：3.97亿 | | | 总股本：3.97亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,526,113,932.73 | 5,377,272,243.65 | 20,926,270,790.4 | 15,758,036,706.01 |
| 营业收入 | 10,526,113,932.73 | 5,377,272,243.65 | 20,926,270,790.4 | 15,758,036,706.01 |
| 二、营业总成本 | 10,091,091,101.37 | 5,065,165,311.08 | 20,015,831,005.51 | 14,995,915,128.07 |
| 营业成本 | 9,427,713,105.57 | 4,755,631,119.24 | 18,614,576,270.41 | 14,043,758,870.81 |
| 税金及附加 | 32,531,342.92 | 15,251,305.38 | 62,711,783.41 | 45,941,277.59 |
| 销售费用 | 313,573,337.77 | 146,025,420.59 | 678,428,881.56 | 426,113,155.55 |
| 管理费用 | 197,387,275.73 | 95,068,227.75 | 403,752,085.4 | 290,888,480 |
| 研发费用 | 20,705,748.74 | 12,535,410.16 | 38,474,037.29 | 30,487,829.54 |
| 财务费用 | 99,180,290.64 | 40,653,827.96 | 217,887,947.44 | 158,725,514.58 |
| 其中:利息费用 | 90,718,016.33 | 36,945,585.4 | 200,576,799.02 | 149,363,017.64 |
| 其中:利息收入 | 14,799,481.61 | 6,313,654.87 | 29,016,502.59 | 21,326,245.51 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 1,107,451.3 | 1,108,577.08 | -52,357.96 | 248,767.82 |
| 资产处置收益 | -259,646.16 | -308,888.73 | 241,629.05 | 117,400.23 |
| 资产减值损失(新) | - | - | -14,201,258.09 | - |
| 信用减值损失(新) | -9,794,098.6 | -42,162,529.34 | -34,312,784.15 | -25,208,309.88 |
| 其他收益 | 8,149,567.42 | 5,064,708.72 | 20,270,060.53 | 17,068,032 |
| 四、营业利润 | 434,226,105.32 | 275,808,800.3 | 882,385,074.27 | 754,347,468.11 |
| 加:营业外收入 | 5,943,019.12 | 5,342,844.34 | 6,597,168.89 | 3,102,507.86 |
| 减:营业外支出 | 14,782,341.04 | 8,008,845.79 | 19,040,516.43 | 8,937,737.34 |
| 五、利润总额 | 425,386,783.4 | 273,142,798.85 | 869,941,726.73 | 748,512,238.63 |
| 减:所得税费用 | 54,027,107.91 | 47,688,629.93 | 149,405,334.7 | 94,555,996.96 |
| 六、净利润 | 371,359,675.49 | 225,454,168.92 | 720,536,392.03 | 653,956,241.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 371,359,675.49 | 225,454,168.92 | 720,536,392.03 | 653,956,241.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 369,170,965.76 | 224,586,456.96 | 709,463,803.15 | 645,713,103.42 |
| 少数股东损益 | 2,188,709.73 | 867,711.96 | 11,072,588.88 | 8,243,138.25 |
| 扣除非经常损益后的净利润 | 367,054,304.98 | 222,868,059.25 | 699,112,627.45 | 633,529,512.28 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.93 | 0.64 | 1.79 | 1.63 |
| (二)稀释每股收益 | 0.93 | 0.64 | 1.79 | 1.63 |
| 九、综合收益总额 | 371,359,675.49 | 225,454,168.92 | 720,536,392.03 | 653,956,241.67 |
| 归属于母公司股东的综合收益总额 | 369,170,965.76 | 224,586,456.96 | 709,463,803.15 | 645,713,103.42 |
| 归属于少数股东的综合收益总额 | 2,188,709.73 | 867,711.96 | 11,072,588.88 | 8,243,138.25 |
| 公告日期 | 2026-08-28 | 2026-04-30 | 2026-04-30 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |